ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere

Tomasz M. Beer

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


ASCENT, the Androgen-Independent Prostate Cancer (AIPC) Study of Calcitriol Enhancing Taxotere, is a double-blind, placebo-controlled randomized clinical trial designed to determine if DN-101, a high-dose oral formulation of calcitriol designed for cancer therapy, significantly increases the proportion of patients who have >50% reduction in serum prostate-specific antigen (PSA) levels in response to docetaxel. The secondary goals of ASCENT are to evaluate the effect of DN-101 combined with docetaxel on PSA progression-free survival, tumour response rate in measurable disease, tumour progression-free survival, skeletal morbidity-free survival, clinical progression-free survival, and overall survival, and to examine the safety and tolerability of DN-101 combined with docetaxel. ASCENT builds on phase I work showing that weekly dosing allows substantial dose-escalation of calcitriol, the natural ligand for the vitamin D receptor, and on phase II work that suggested that adding weekly high-dose 'pulse' calcitriol may enhance the activity of weekly docetaxel in patients with AIPC. The preclinical rationale for calcitriol and its combination with docetaxel for prostate cancer therapy is reviewed, as are the key clinical trials that led to the development of ASCENT. The ASCENT design and its strengths and limitations are presented.

Original languageEnglish (US)
Pages (from-to)508-513
Number of pages6
JournalBJU international
Issue number4
StatePublished - Sep 2005
Externally publishedYes


  • Calcitriol
  • Prostate cancer
  • Vitamin D

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere'. Together they form a unique fingerprint.

Cite this